FOP patient registry for people with confirmed diagnoses
Part of Bones, joints & muscles, Cancer clinical trials.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of FOP.
- You (or your parent/legal guardian) must agree to join the study.
- You must be able to provide written informed consent (a signed permission form).
- No other health conditions automatically stop you from joining.
- The study is focused on enrollment and ongoing information collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
This study tests whether garetosmab, a new medication, can slow or stop abnormal bone formation in children with FOP (a rare condition where muscle and connective tissue gradually turn into bone). The goal is to help young people with FOP move better and have fewer joint limitations.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This study is building a national registry (a database) for people with Oculo-Pharyngeal Muscular Dystrophy (OPMD) in Israel. Joining will help researchers understand how OPMD progresses over time and may lead to better care.
This study is a registry, meaning it collects health information about people with osteogenesis imperfecta (OI) to better understand the condition. It may help researchers learn what care works best and how OI varies from person to person.
Hear when a new Fibrodysplasia Ossificans Progressiva (FOP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.